A Real World Study of Regogfinib in HCC

NCT05557656 · clinicaltrials.gov ↗

UNKNOWN

Status

800

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Regorafenib 40 MG

Sponsor

Zhongda Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]